English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Dr John Brandsema Highlights Progress in SMA Treatment and Improved Outcomes for Patients
The introduction of 3 FDA-approved therapies for spinal muscular atrophy is enabling clinicians to treat the disease completely different from how it was handled in the past.
Prior to 2016, the only options available to patients diagnosed with spinal muscular atrophy (SMA) was best supportive care. However, the introduction of 3 FDA-approved therapies—nusinersen in 2016, onasemnogene abeparvovec in 2019, and risdiplam in 2020—has changed the treatment paradigm.
Now, patients are being identified screened earlier, diagnosed sooner, and treated faster to alter the disease trajectory, keep patients stable, and improve outcomes for patients with SMA, explained John Brandsema, MD, neuromuscular section head, Children’s Hospital of Philadelphia.
During an interview with The American Journal of Managed Care® (AJMC®), Brandsema reviewed the treatment landscape, the importance of diagnosing SMA early, and discussions with families and patients when considering the 3 therapies.
BookmarkRelated Content
-
The SMA France National Registry: Already Encouraging ResultsSpinal muscular atrophy is a debilitatin...
-
Implications of Circulating Neurofilaments for Spinal Muscular Atrophy Treatment Early In Life: A Case SeriesThis longitudinal cohort study aimed to ...
-
Patient of the Month: GiannaAfter noticing that her daughter was una...
-
Managing Pregnancy in a Spinal Muscular Atrophy Type III Patient in Indonesia: A Case ReportSpinal muscular atrophy (SMA) is a genet...
-
Once-Daily Risdiplam Beneficial in Patients With Types 2 and 3 SMA: LancetOnce-Daily Risdiplam is beneficial in pa...
-
Spinal Muscular Atrophy 2019: SMA Pathophysiology, Diagnosis and Clinical Presentationshttps://www.youtube.com/watch?v=cUuWue8M...
-
SMA Type 1 – Looking After Your Child Who Has Had a Recent DiagnosisThe aim of everyone involved in your chi...
Powered by
In partnership with
